Video

Dr. Eileen O'Reilly on Factors to Consider in Pancreatic Cancer Treatment

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

Oncologists will often take into consideration patients’ preference with factors such ability to come in often for infusions, fear of alopecia, and costs of care, which is becoming increasingly prevalent in the conversation regarding treatment planning, O’Reilly says.

Comorbidities and performance status are also considered, and as more therapies for pancreatic become available, more oncologists are questioning whether second-line therapies should be considered when choosing the initial treatment.

<<<

View more from the 2016 World Congress on GI Cancer

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.